Season 2 - Ep. 22: Lipid-lowering therapy beyond statins - Management of cardiac fibroelastoma

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies What is new in lipid management – therapeutic options beyond statins Cardiac papillary fibroelastomas Snapshots Host: Rick Grobbee Guests: Stephan Achenbach, Carlos Aguiar, Kyle Klarich, Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/1157 Disclaimer ESC TV Today and ESC 365, the cardiology knowledge hub are supported by Bristol Myers Squibb. The scientific content and opinions expressed in this programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Rick Grobbee, Kyle Klarich and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Konstantinos Koskinas has declared to have potential conflicts of interest to report: speaker fees / honoraria from Amgen, Daiichi-Sankyo, Sanofi.  Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.